Small-molecule inhibitors originally developed to treat cancer, such as farnesyl transferase inhibitors, MEK inhibitors, ERK inhibitors and several more, provide opportunities to modulate pathway activity and therapeutically treat developmental disorders caused by germline RAS/MAPK hyperactivation (Dombi et al., 2016). The gene discussed is MAP2K7; the disease is cancer.